State Board of Administration of Florida Retirement System boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Rating) by 4.4% during the second quarter, HoldingsChannel.com reports. The fund owned 25,677 shares of the biopharmaceutical company’s stock after buying an additional 1,090 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Agios Pharmaceuticals were worth $569,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WINTON GROUP Ltd grew its holdings in shares of Agios Pharmaceuticals by 18.0% during the first quarter. WINTON GROUP Ltd now owns 22,138 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 3,382 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth about $439,000. Rock Springs Capital Management LP grew its position in shares of Agios Pharmaceuticals by 0.7% in the 1st quarter. Rock Springs Capital Management LP now owns 2,665,275 shares of the biopharmaceutical company’s stock valued at $77,586,000 after buying an additional 18,650 shares during the last quarter. Edgewood Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $582,000. Finally, SG Americas Securities LLC raised its holdings in Agios Pharmaceuticals by 120.6% during the 2nd quarter. SG Americas Securities LLC now owns 39,737 shares of the biopharmaceutical company’s stock worth $881,000 after purchasing an additional 21,723 shares during the last quarter.
Wall Street Analysts Forecast Growth
AGIO has been the topic of several recent analyst reports. The Goldman Sachs Group upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “neutral” rating and boosted their target price for the company from $17.00 to $32.00 in a report on Thursday. StockNews.com started coverage on Agios Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Finally, SVB Leerink increased their target price on shares of Agios Pharmaceuticals from $33.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $53.43.
Agios Pharmaceuticals Trading Down 1.3 %
Agios Pharmaceuticals (NASDAQ:AGIO – Get Rating) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.49) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.22. The business had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.24 million. During the same quarter last year, the business posted ($1.48) earnings per share. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.28 EPS for the current fiscal year.
Agios Pharmaceuticals Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
- Get a free copy of the StockNews.com research report on Agios Pharmaceuticals (AGIO)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.